Clinical stage >= TNxM or TanyN+ disease for which radical or partial nephrectomy is planned
Planned surgery or radiation therapy during protocol treatment
Have a planned major surgery.
Prior neoadjuvant chemo or biologic therapy for current breast cancer within  weeks prior to planned surgery [Period ]
Any other cancer treatments within  weeks of planned study treatment
Current, recent (within  days prior to Day ), or planned use of any antitumor therapy outside this study
Patients must have surgery planned to remove the desmoid tumor and either:
Patients must be able to cooperate fully with all planned protocol therapy
Planned procedure or surgery during the study
Planned to receive Erbitux (Cetuximab) or similar targeted therapy between Baseline and  weeks post-RT
Patients who have received another cancer therapy within  weeks before the planned day for the apheresis
Patients who receive or are planned to receive any other investigational product within the  weeks before the planned day for the first NKR- administration
Last dose of AZA or DAC within  months before the planned date of randomization; however, must be off these treatments for ?  weeks before randomization
Investigational therapy within  weeks of planned randomization
Patients receiving immunotherapy for non-cancer related treatment within <  weeks of first planned dose of study treatment will be excluded.
Prior (within last  months) or future planned therapeutic surgery for the treatment of the existing lung cancer
Current or planned glucocorticoid therapy, with the following exceptions:
Patients who have the ability to collaborate planned follow-up
Planned treatment with the LR-IUD for CAH or grade  EC by primary physician
Elective procedure (colectomy, gynecological, or thoracic) where at least one vessel is planned to be transected by the ENSEAL X device per its instructions for use;
Patients who are receiving or are planned to start topical chemotherapeutics, retinoids or imiquimod to other lesions that are not planned for enrollment are eligible; however, the lesion being considered for enrollment should not be under active therapy with these topical agents immediately prior to enrollment.\r\n* Use of topical chemotherapeutics, retinoids or imiquimod on the lesion that is a candidate for enrollment must be halted at least  hours prior to enrollment in the study.
Planned vacation or dental work during the study phase
Participating in a chronic transfusion program (pre-planned series of transfusions for prophylactic purposes)
Planned treatment site(s) accompanied by objective evidence of secondary radiculopathy or neurologic compromise
Planned radiation treatments at Mayo Clinic Rochester
Evidence of an infection within  days of planned injection.
Must have had a relapse or progressive disease (PD) after having received  or more prior lines of systemic therapy. Note: A line of therapy is defined as  or more cycles of a planned treatment program; this may consist of  or more planned cycles of single-agent therapy or combination therapy, as well as a sequence of treatments administered in a planned manner. For example, a planned treatment approach of induction therapy followed by autologous stem cell transplantation (SCT), followed by maintenance is considered  line of therapy. Typically each line of therapy is separated by PD.
Subjects must be scheduled for surgery at Medical University of South Carolina (MUSC) no less than  days from the planned start of day  and no more than  days from the planned start of day 
At the time of study enrollment, patients must have at least  months of adjuvant trastuzumab planned
Patients have planned invasive dental procedures during the course of the study
Patients in which hemithoracic radiation therapy is planned
Planned to get local surgery
Planned goal TSH suppression .-. mU/L for at least  weeks postoperatively
Planned postoperative TSH goal different than .-. mU/L
The parent study is closed or planned to be closed; and
Planned use of maintenance or consolidative therapy
Planned stereotactic body radiation therapy (SBRT) for the pulmonary metastases
Planned pre-operative chemotherapy (patients with planned post-operative chemotherapy are eligible)
Use of chemotherapy within  weeks of the planned start of radiation therapy
Planned treatment with TTFields therapy.
Planned resectional surgery for MPM (extrapleural pneumonectomy [EPP] or pleurectomy and decortication [P/D])
No history of prior radiotherapy overlapping with high dose region of planned SABR course
For patients with rHGG, the patient intends to undergo treatment with the Gliadel wafer at the time of planned resection (ie, on-study surgery) or has received the Gliadel wafer <  days from the date of planned resection.
Systemic chemotherapy delivered or planned to be delivered within (+/-)  days of SRS re-irradiation
Prior radiation therapy in the planned treatment field
Patient can have prior SRS to lesions other than the one planned for neoadjuvant SRS and resection
Planned concurrent WBRT
Planned major surgery
Planned use of Optune
No planned systemic treatment is allowed within one week after treatment
Planned IMRT (Intensity-Modulated Radiotherapy)
Planned administration of cisplatin administered weekly or tri-weekly during RT
Planned to receive concomitant single agent chemotherapy with cisplatin given either weekly or tri-weekly
Planned neoadjuvant chemoRT treatment must conform to NCCN guidelines.
Has received a T-cell product within  weeks prior to planned infusion of genetically modified T cells.
Patients planned for pre-operative chemotherapy or those with known metastatic breast cancer
Patients with a planned use of Novo-TTF (Optune) are ineligible
Planned invasive dental procedures during the course of study
Planned major surgery during the study
Planned radiation therapy after transplant
No planned major surgery
Planned major surgery
Patients must have successfully completed therapy with sipuleucel-T within - days of planned CYT study drug treatment
History of metastatic cancer diagnosed less than  years prior to the first planned dose of PF-
Patients with multiple, ipsilateral pulmonary nodules (T or T) are eligible if a definitive course of daily fractionated radiation therapy (RT) is planned
Patients must have had either breast-conserving surgery with planned radiation therapy or total mastectomy (with or without planned postmastectomy radiation); patients must have clear margins from both invasive breast cancer and DCIS (as per local institutional guidelines); lobular carcinoma in situ (LCIS) at the margins is allowed
Patients must not have received prior WBRT (previous SRS/SRT done at least  weeks from the planned start of WBRT is acceptable); patients planned upfront to undergo SRS/SRT/fractionated boosts or neurosurgery after WBRT are not eligible; however, these treatments/procedures can be performed once the dose limiting toxicity (DLT) assessment has been completed, if felt clinically necessary
Planned liver directed therapy or radiation therapy
Patients whose entry to the trial will cause unacceptable clinical delays in their planned management
The trial is open only to women with primary endometrioid adenocarcinoma of the uterine corpus (all histologic grades and stages) who are planned and appropriate for primary surgical treatment
Breast surgery planned
Current or planned use of systemic therapy for extracranial primary tumor
Have a planned major surgery.
Current or planned pregnancy within the next three months (females only)
Reduction mammoplasty if DCRT or proton APBI are planned
Chemotherapy <  weeks prior to the first planned dose of study treatment
Patients planned invasive dental procedures
Intercurrent illness likely to prevent protocol therapy or conventional planned therapy
Participants who relapsed from at least  previous treatment AND additionally were refractory to at least  previous treatment. For the purposes of this study, refractory disease was defined as disease progression on treatment or progression within  days after the last dose of a given therapy. A line of therapy was defined as  or more cycles of a planned treatment program. This may have consisted of  or more planned cycles of single-agent therapy or combination therapy, as well as a sequence of treatments administered in a planned manner. For example, a planned treatment approach of induction therapy followed by autologous stem cell transplantation, followed by maintenance was considered  line of therapy. Autologous and allogenic transplants were permitted.
Women with planned treatment of primary definitive chemoradiation therapy
Women with planned treatment of radiotherapy only (without chemotherapy)
Chemotherapy given on the day of the planned radiotherapy treatment
If chemotherapy is planned, it must begin no earlier than two weeks following completion of radiation therapy
Planned first-line chemotherapy contains a proteasome-inhibiting agent administered weekly
Change in chemotherapy agent is planned  days before or after enrollment (change in dose(s) permitted),
Major elective surgery to the spine in same region as the index vertebra(e) is planned within  month following the ablation and cement procedure,
Planned invasive dental procedure for the course of the study
Planned to be treated by active surveillance
Planned use of any treatment for PTCL during the course of the study.
Has, at the planned initiation of study drug, an uncontrolled infection.
Anti-cancer chemotherapy or biologic therapy if administered prior to the first planned dose of BBI/placebo within period of time equivalent to the usual cycle length of the regimen. An exception is made for oral fluoropyrimidines (e.g. capecitabine, S-), where a minimum of  days since last dose must be observed prior to the first planned dose of BBI/placebo.Radiotherapy, immunotherapy, or investigational agents within four weeks of first planned dose of BBI/placebo, with the exception of a single dose of radiation up to  Gray (equal to  RAD) with palliative intent for pain control up to  days before randomization.
Macroscopic complete resection of the primary tumor must be planned
Planned to receive standard cisplatin chemotherapy administered either weekly or every third week.
Planned biopsy or resection of recurrent tumor for therapeutic and/or diagnostic purpose, and with adequate bone marrow, hepatic, cardiac, and renal function to undergo this planned procedure
Planned invasive dental procedures for the course of the study.
Planned initiation, termination, or dose alteration of hydroxyurea during the study
Current or planned glucocorticoid therapy, with the following exceptions:
Chemotherapy within  weeks of first planned fraction of SBRT
Planned invasive dental procedure for the course of the study
Sarcomas where radiation is not planned preoperatively
For stage I-III disease, patients should be - months post-completion of surgery, radiation therapy and/or chemotherapy with no further planned treatment during the -week study and no evidence of disease
Beginning a new course of chemotherapy and/or immunotherapy (with a side effect profile that includes the symptoms monitored by SCH) that is planned for a minimum of three cycles
Planned chemotherapy during radiosurgery
Planned administration of bedside LR PLT transfusion(s)
INCLUSION CRITERIA:\n\n          . Subjects must be ?  years old and have a life expectancy ?  weeks\n\n          . Histologically proven, primary (de novo) GB that has recurred or progressed (first or\n             second recurrence, including this recurrence)\n\n          . Confirmation that archived tissue is available from first diagnosis of GB for\n             biomarker analysis\n\n          . Recurrent tumor must be supratentorial, contrast-enhancing GB no smaller than  cm x \n             cm (largest perpendicular dimensions) and no larger than  cm maximum in a single\n             direction based on MRI taken within  days prior to catheter placement\n\n          . Karnofsky Performance Score (KPS) ? \n\n          . Subjects must be able and willing to undergo multiple brain MRI examinations\n\n          . Subjects must be able and willing to comply with all study procedures\n\n          . Any related toxicities following discontinuation of prior GB therapies must have\n             resolved to CTCAE Grade  or lower prior to inclusion in this study\n\n        EXCLUSION CRITERIA:\n\n          . Prior treatment with cytotoxic chemotherapy\n\n               . Temozolomide (standard induction and / or maintenance dosing) within the past \n                  weeks prior to planned infusion\n\n               . \Metronomic\ Temozolomide (low-dose, continuous administration) within the past \n                  days prior to planned infusion\n\n               . Nitrosoureas within the past  weeks prior to planned infusion\n\n               . Treatment with any other cytotoxic agent within the past  weeks prior to planned\n                  infusion\n\n          . Prior investigational treatment within the past  weeks or prior immunotherapy or\n             antibody therapy within the past  weeks prior to planned infusion\n\n          . Prior treatment with bevacizumab (Avastin) or other vascular-endothelial growth factor\n             (VEGF) inhibitors or VEGF-receptor signaling inhibitors within the past  weeks prior\n             to planned infusion\n\n          . Prior therapy that included interstitial brachytherapy or Gliadel Wafers (carmustine\n             implants) within the past  weeks prior to planned infusion\n\n          . Prior surgery (including stereotactic radiosurgery and biopsy procedures) within the\n             past  weeks prior to planned infusion\n\n          . Ongoing Optune therapy within  days of planned infusion\n\n          . Secondary GB (i.e., GB that progressed from low-grade diffuse astrocytoma or AA)\n\n          . Known mutation in either the isocitrate dehydrogenase  (IDH) or the IDH gene.\n\n          . Tumor in the brainstem (not including fluid-attenuated inversion recovery [FLAIR]\n             changes), an infratentorial tumor, diagnosis of gliomatosis cerebri (highly\n             infiltrative T hyperintense tumor with ill-defined margins encompassing at least\n             three lobes of the brain.\n\n         . Tumor with a mass effect (e.g. - cm midline shift)\n\n         . Subjects with tumors for which the preponderance of tissue is not of the type in which\n             convection would be possible (e.g. preponderance of cystic component)\n\n         . Tumor with geometric features that make them difficult to adequately cover the tumor\n             volume with infusate by using CED catheters\n\n         . Clinical symptoms that are thought by the Investigator to be caused by uncontrolled\n             increased intracranial pressure, hemorrhage, or edema of the brain\n\n         . Any condition that precludes the administration of anesthesia\n\n         . Known to be human immunodeficiency virus positive\n\n         . Concurrent or a history of any significant medical illnesses that in the\n             Investigator's opinion cannot be adequately controlled with appropriate therapy or\n             would compromise the subject's ability to tolerate the study drug therapy and/or put\n             the subject at additional risk or interfere with the interpretation of the results of\n             this trial\n\n         . Known history of allergy to gadolinium contrast agents\n\n         . Presence of another type of malignancy requiring treatment within <  years prior to\n             the screening visit, except for adequately treated carcinoma in-situ of the cervix,\n             prostate cancer not actively treated, and basal or squamous cell carcinoma of the skin
No planned reconstructive surgery with flap repair during trial and follow-up period
No surgery planned in the next  months
Planned for bilateral axillary surgery
Patient is planned to receive interventional procedures (i.e. surgery) that may affect study outcomes
Treatment with antithymocyte globulin within  days of planned infusion of virus  specific, antigen selected T cells
Treatment with virus  specific T cells within  weeks ( days) of planned infusion
No surgery planned in the next  months
Primary treatment is active surveillance (AS) with planned annual surveillance biopsies
Planned surgeries or radiation treatment within  weeks following study inclusion
Willingness to be followed for the planned duration of the trial ( years)
Planned treatment with R-CHOP chemotherapy
Known or suspected gynecologic or other abdominal malignancy (such as colorectal, liver, pancreatic, kidney and stomach) for which laparotomy is planned
Planned less than two week hospitalization
Planned participation in the Gynecologic Enhanced Recovery Pathway
Treatment plan to receive a continuous course of IMRT delivered as single daily fractions of . to . Gy with a cumulative radiation dose between  Gy and  Gy. Planned radiation treatment fields must include at least two oral sites (buccal mucosa, floor of mouth, tongue, soft palate) that are each planned to receive a total of >  Gy. Patients who have had prior surgery are eligible, provided they have fully recovered from surgery, and patients who may have surgery in the future are eligible.
No planned ostomy creation at time of enrollment
Planned continuous antibiotic treatment during RT
Planned surgery anticipated during the intervention period
Abnormal global longitudinal strain (< %, or a % decrease of >= % from baseline) prior to initiation of planned anti-HER therapy
Planned fractionated external beam radiotherapy to be delivered by opposing, tangential beams to . Gy in  fractions with a planned photon or electron boost of  Gy in  fractions (for a total of  fractions)
Planned radiation therapy or surgery to the bone (does not include procedures performed before randomization)
Planned invasive dental procedures
No planned surgery anticipated in the -month intervention period
Patients with planned laparoscopic PD
Planned stereotactic body radiation therapy (SBRT)
Surgical intervention is planned primary mechanism of local control
At least  night of planned inpatient stay
Planned total laryngectomy at Barnes Jewish Hospital (BJH)
Planned outpatient surgery
Women who are being seen at the Women's Health Center by the Gynecologic Oncology group at the University of Minnesota if planned surgery includes an exploratory laparotomy
Patient receiving any investigational drug for hyperuricemia within  days of planned first treatment with rasburicase
Subjects who are planned to receive >  mg flat dose of vinca alkaloids
Patients who have been treated with chemotherapy or radiation within two weeks of planned study enrollment; this does not include hydroxyurea or ruxolitinib, which may be continued until start of conditioning therapy
Planned cisplatin treatment restricted to the following treatment course criteria:\r\n* Dose: >  mg/m^\r\n* Frequency: every (q)-q weeks\r\n* Cycles:  maximum
Planned concurrent administration of cisplatin chemotherapy (either  mg/m^ every  weeks or - mg/m^ every week)
Split-course RT is planned
Split-course RT is planned
Planned continuous antibiotic treatment during RT
Current or planned use of other agents for treating hot flashes
Current or planned use of any type of antidepressants
Not planned for surgical intervention
EXCLUSION - PATIENT: Breast biopsy or surgical intervention planned before the test RSI-MRI in this study
The patients planned cancer management is radiation to the liver with or without chemotherapy
No recent or planned immunotherapy
No future cancer therapy planned
Participants need to have had a mammogram within  days of day  (normal/benign bi-rads  or ) with no suspicion of a mass and no further routine breast imaging planned during the course of the study ( weeks)
The patient is a candidate for surgical resection, with no planned neoadjuvant chemotherapy, and there is a planned surgery for the primary colorectal cancer
Prior or planned bariatric surgery
At randomization, their planned course of antibacterial drug treatment for CDI is longer than  days
Current or planned pregnancy
Men on stable doses of -alpha reductase inhibitors are eligible as long as there is no planned dose change while on study
Current or planned pregnancy
Has evidence of cancer at the time of enrolment, or has surveillance tests planned within  weeks after enrollment
Patient planned to receive altered fractionation radiotherapy or multiple fractions per day
Pregnancy in the last  months/planned within the next  years or currently lactating
Planned reconstructive surgery with flap repair during study period
Planned partial breast radiation
Planned use of ex vivo or in vivo T-cell depletion
Subject is planned to undergo either of the following:
Current or planned pregnancy within the next three months (females only)
Planned use of anti-thymocyte globulin (ATG) or alemtuzumab in conditioning regimen.
planned treatment course to include Cisplatin and radiation therapy, cumulative prescription dose between - Gy
Insufficient leukemia or MDS specimen available for profiling from diagnosis or recurrence; or bone marrow evaluations NOT planned for clinical care; or peripheral blast percentage < % AND clinical blood draw not planned; or patient sample did NOT already complete rapid heme panel leukemia profiling clinically
Surgery/biopsy planned as part of clinical care that is anticipated to yield sufficient material to meet the minimum requirements for profiling; OR
Prior RT is allowed and must have been completed more than  days before planned study entry\r\n* Note: For re-irradiation cases, standard departmental guidelines should be followed so as to not exceed normal tissue
Prior radiation therapy which would provide significant dose overlap with the planned target volume(s) delivered within  days of enrollment or registration
Cohort B only: (N =  evaluable patients): Planned nephrectomy within  weeks following protocol scan
Planned administration of any NET therapy between scan  and , except for short acting octreotide
Men with prostate cancer and known bone metastases planned for new systemic therapy and/or radiotherapy and who have a planned clinically indicated staging multi-detector computed tomography (MDCT)
Planned craniotomy and resection or biopsy
Participant must be receiving a planned lymphoscintigraphy procedure
Patients must have planned treatment with doxorubicin:\r\n* Patients with sarcoma must have an initial planned regimen including  mg/m^ doxorubicin for at least  cycles; NOTE: patients can be on additional chemotherapeutic agents \r\n* Patients with lymphoma must have an initial planned regimen including  mg/m^of doxorubicin for at least  cycles; NOTE: patients can be on additional chemotherapeutic agents\r\n* Patients with breast cancer must have an initial planned regimen including  mg/m^ of doxorubicin for at least  cycles; breast cancer patient enrollment will stop once  breast cancer patients have been enrolled; NOTE: patients can be on additional chemotherapeutic agents
Planned procedures or therapies in between SOC scans and study scan on s-DCT, e.g., biopsy or excision of lung lesion
Planned thorascopic, robotic or laparoscopic surgical approach
Subjects must be planned for resection (this includes localized resectable disease or patients with metastatic disease with planned palliative resection) and scheduled to begin neoadjuvant chemotherapy
Patients must not be planned for lung resection after radiation therapy
No international travel planned during the next  months
Planned quit date within the next two months
Serum albumin must be planned to be collected after admission, but prior to treatment
Previous exposure to OTL . Known FR-negative ovarian cancer . Planned surgical debulking via laparoscopy or robotic surgery, with no intent of laparotomy.
Planned surgical approach via laparoscopy or robotic surgery